BranchLab Raises $26M in Series A Funding Led by McKesson Ventures

The company plans to use the funding to expand enterprise deployments, strengthen integrations across the healthcare and media industries and continue developing its unified AI platform for pharmaceutical commercialization.

BranchLab has developed a unified AI platform that helps pharmaceutical companies and their agencies identify, target, and optimize patient and healthcare professional (HCP) audiences in near real time. Leading pharma companies already use the platform and have improved marketing performance by an average of nearly 70% across multiple therapeutic areas.

At the core of BranchLab’s platform is a transformer based AI architecture that allows models to train on healthcare data within customer-controlled environments while using only non sensitive demographic and media data for deployment. This approach greatly speeds up pharmaceutical commercialization workflows, reducing processes that once took months down to just minutes.

Andrew Bouldin, Managing Partner at FCA Venture Partners, said pharmaceutical companies have invested heavily in data and analytics, but much of that information still sits outside core operational systems. He said BranchLab’s approach of running AI models inside regulated environments and connecting them directly to execution systems represents a major shift in how pharmaceutical commercialization can work, helping data and activation systems operate together in real time.

"Healthcare is entering a new era of responsible AI within regulated environments," said Cris De Luca, Sanofi Ventures. "BranchLab has the potential to become a core commercial intelligence layer, putting this capability directly in the hands of pharma teams to connect therapies with patients across next generation digital environments."

Read More:9amHealth Raises $26M in Series B Funding Led by Define Ventures

"The more we learned about BranchLab, the more we saw the possibility to transform the way patients learn about and get started on the right therapies," said Carrie Williams, partner at McKesson Ventures. "Combining a deep understanding of the patient journey with a future-proofed approach to patient activation could enable an evolved patient therapy experience, one that seamlessly bridges privacy-first audience targeting with patient access, affordability and preference."

"Pharma has long had access to rich data, but using it quickly—and responsibly—has been the challenge," said Josh Walsh, CEO of BranchLab. "BranchLab solves this by turning privacy-safe, aggregated data into real-time insights that connect directly to activation. Teams can move faster, reach the right audiences more effectively, and drive better outcomes without relying on sensitive or individual-level information."

About BranchLab

Founded by Michael Parkes, Chris Cagle, and Josh Walsh, BranchLab is an AI-powered healthcare commercialization platform that helps healthcare organizations and agencies connect patients, providers, and caregivers with important therapies and resources. Built for a privacy focused healthcare environment, the company improves commercialization performance without relying on individual level health data while helping organizations operate more efficiently and responsibly.

Read More:Anomaly Raises Additional $17M in Funding Led by Sound Ventures